CCKBR and medullary thyroid gland carcinoma: Previous experience from small-scale studies performed in MTC patients using radiolabelled minigastrin analogues at a peptide dose of 5–10 μg (Froberg et al., 2009) and from the routine pentagastrin test, undesirable effects were recorded due to ligand-induced CCK2R-activation.